Skip to main content
. Author manuscript; available in PMC: 2012 Oct 9.
Published in final edited form as: Ann Rheum Dis. 2012 May 5;71(11):1872–1880. doi: 10.1136/annrheumdis-2011-201180

Figure 4. Profile of Anxa1, Fpr1 and Fpr2 gene product expression in ankle joints of AnxA1+/+ and AnxA1−/− mice treated with Dex.

Figure 4

AnxA1+/+ and AnxA1−/− mice were given an intraperitoneal injection of K/BxN serum (50 μl at day 0 and day 2) and then received vehicle or Dex (10 μg i.p. daily). Quantitative real-time PCR was performed on cDNA from left ankle joints of mice from each experimental group (Day 10). The Anxa1, Fpr1 and Fpr2 genes were analysed with all Ct values normalised to endogenous Gapdh (4 mice per group). Naïve joints were set as the calibrator samples. Mean RQ values ± SE shown here were calculated using 2−(ΔΔCt) method. *p<0.05 vs. naïve; §p<0.05 vs. appropriate vehicle control; #p<0.05 vs. AnxA1+/+ group (Student’s t test).